A β-Arrestin 2-Biased Dopamine Receptor Type 2 (DRD2) Agonist Is More Efficacious Than Cabergoline in Reducing Cell Proliferation in PRL-Secreting but Not in Non-Functioning Pituitary Tumor Cells

A β-Arrestin 2-Biased Dopamine Receptor Type 2 (DRD2) Agonist Is More Efficacious Than Cabergoline in Reducing Cell Proliferation in PRL-Secreting but Not in Non-Functioning Pituitary Tumor Cells

The molecular events underlying the variable effectiveness of dopamine receptor type 2 (DRD2) agonists in pituitary neuroendocrine tumors (PitNETs) are not known. Besides the canonical pathway induced by DRD2 coupling with Gi proteins, the β-arrestin 2 pathway contributes to DRD2′s antimitotic effec...

Full description

Bibliographic Details
Main Authors: Genesio Di Muro, Federica Mangili, Emanuela Esposito, Anna Maria Barbieri, Rosa Catalano, Donatella Treppiedi, Giusy Marra, Emma Nozza, Andrea G. A. Lania, Emanuele Ferrante, Marco Locatelli, Maura Arosio, Erika Peverelli, Giovanna Mantovani
Format: Article
Language:English
Published: MDPI AG 2023-06-01
Series:Cancers
Subjects:
dopamine receptor type 2
pituitary tumors
beta arrestin 2
Online Access:https://www.mdpi.com/2072-6694/15/12/3218

Similar Items

Similar Items